This Week in Endocrinology — Jul 14, 2026

Welcome to This Week in Endocrinology. This week we're covering 10 notable papers spanning the safety, cardiovascular effects, and clinical utility of incretin therapies, advanced management strategies in type 1 diabetes, and emerging diagnostic and therapeutic paradigms across metabolic and rare endocrine disorders. Let's dive in.

We begin with a highly discussed safety concern regarding nonarteritic anterior ischemic optic neuropathy, or NAION, associated with glucagon-like peptide-1 receptor agonists. Two major target trial emulations published in the Annals of Internal Medicine address this head-on. First, a United States-based observational study analyzed a large commercial claims database of patients aged 18 to 65 with type 2 diabetes initiating a GLP-1 receptor agonist, an SGLT-2 inhibitor, or a DPP-4 inhibitor [1]. The investigators adjusted for more than 80 covariates to mitigate confounding. Over an 18-month follow-up, the absolute risk of ischemic optic neuropathy was exceptionally low but showed a statistically significant elevation among GLP-1 receptor agonist users. Specifically, the risk was roughly 8.5 per 10,000 patients using GLP-1 receptor agonists compared to 5.5 per 10,000 using SGLT-2 inhibitors, and 7.8 versus 4.2 per 10,000 when compared to DPP-4 inhibitors. This translates to a number needed to harm of over 3,300 and 2,700, respectively. Interestingly, the majority of these events occurred in men and individuals older than 50, and the risk differences were substantially attenuated in patients who were only on metformin monotherapy at baseline. This potential signal is further clarified by a nationwide Swedish cohort study, also published in the Annals of Internal Medicine, which followed over 100,000 GLP-1 receptor agonist initiators and over 180,000 SGLT-2 inhibitor initiators for a median of about one and a half years [2]. They found that the 1-year risk of anterior ischemic optic neuropathy was 0.04% in the GLP-1 group compared to 0.02% in the SGLT-2 inhibitor group, representing a nearly doubled relative risk. However, when the investigators restricted the analysis to patients receiving metformin at baseline—a proxy used to control for diabetes severity and duration—the risk differences were substantially reduced and lost statistical significance. Both studies strongly suggest that while a tiny relative risk increase might exist, the absolute risk is incredibly small, and much of the observed association is likely driven by residual confounding from diabetes severity rather than a direct causal effect of the drug.

Beyond safety, how do these agents perform when we try to use them to simplify complex insulin regimens? A target trial emulation utilizing United States Veterans Health Administration electronic health record data, published in the Annals of Internal Medicine, evaluated whether adding a GLP-1 receptor agonist to basal insulin increases the likelihood of successfully discontinuing insulin therapy compared to adding an SGLT-2 inhibitor or a DPP-4 inhibitor [3]. Examining nearly 9,000 matched sets of patients over a three-year period, the researchers found no significant difference in insulin discontinuation rates. Approximately 16.7% of GLP-1 receptor agonist initiators discontinued insulin, which was highly comparable to the 17.9% of SGLT-2 inhibitor initiators and 17.1% of DPP-4 inhibitor initiators. These findings challenge the common clinical assumption that GLP-1 receptor agonists possess a unique therapeutic advantage for facilitating complete insulin withdrawal, suggesting instead that any of these second-line agents can support modest rates of insulin discontinuation in a real-world veteran population. To better understand the physiological mechanisms of these incretin-based therapies, a study published in Diabetes explored the metabolic and cardiovascular actions of a pharmacological glucose-dependent insulinotropic polypeptide, or GIP, infusion during hyperglycemia in patients with type 2 diabetes [10]. Although dual GLP-1 and GIP receptor agonists are highly successful, the independent role of GIP has been debated. The researchers demonstrated that GIP remains biologically active in type 2 diabetes, stimulating insulin secretion and increasing whole-body glucose disposal during hyperglycemia. However, it also modestly attenuated glucagon suppression and actually impaired insulin sensitivity, while simultaneously augmenting heart rate and reducing blood pressure. These complex, dual metabolic and cardiovascular effects highlight that GIP acts through highly nuanced pathways, which may help explain the unique clinical profile of dual-receptor agonists.

Turning our attention to type 1 diabetes, technology and treatment timing continue to redefine clinical care. A single-center study published in Diabetes Care evaluated the real-world impact of initiating the Omnipod 5 hybrid closed-loop system in individuals with type 1 diabetes who suffer from impaired awareness of hypoglycemia, defined by a Gold score of 4 or higher [5]. At baseline, these patients experienced a significantly higher time below range and longer, more frequent episodes of sensor-detected hypoglycemia compared to matched controls with normal hypoglycemia awareness. Twelve months after initiating the hybrid closed-loop system, patients with impaired awareness saw a significant reduction in their time below range, which dropped from 2.8% to 1.7%, alongside a decrease in the weekly number of hypoglycemic episodes. However, the study notes that despite these clear improvements, the overall hypoglycemia burden and frequency of events remained significantly higher in those with impaired awareness compared to controls, indicating that while automated insulin delivery is a powerful tool, it does not entirely eliminate the excess risk associated with impaired awareness. In addition to automated systems, the simple timing of prandial insulin remains a cornerstone of vascular and metabolic health. A randomized, crossover clinical trial published in Diabetologia evaluated whether injecting prandial insulin 15 minutes before a meal compared to 15 minutes after meal initiation affects vascular function in young adults with type 1 diabetes [6]. Using ultrasound imaging, the investigators measured myocardial and skeletal muscle microvascular perfusion, aortic stiffness, and endothelial function. They found that premeal insulin administration significantly blunted postprandial hyperglycemia, leading to a smaller glucose area under the curve. Crucially, this premeal timing also significantly increased myocardial microvascular flow velocity and myocardial microvascular blood flow, an effect not observed with postmeal administration or in the healthy control group. This highlights a direct, acute cardiovascular benefit of proper insulin timing, reinforcing the clinical recommendation of premeal dosing not just for glycemic control, but for microvascular preservation.

Next, we look at the rapidly evolving landscape of obesity management. A review published in The Journal of Clinical Endocrinology and Metabolism highlights how next-generation pharmacotherapies are shifting the treatment paradigm from simple weight reduction to complication-centric, phenotype-guided care [8]. While single-pathway GLP-1 receptor agonists achieve a highly respectable 10% to 15% weight loss, emerging multi-pathway therapies are pushing these boundaries. Dual and triple agonists like tirzepatide, CagriSema, and amycretin have demonstrated weight reductions exceeding 20%, while the triple receptor agonist retatrutide has achieved losses greater than 25%. Beyond the scale, these agents are proving to be disease-modifying, showing robust clinical benefits in preventing diabetes, reducing cardiovascular events, improving heart failure symptoms, decreasing obstructive sleep apnea severity, resolving metabolic dysfunction-associated steatohepatitis, slowing chronic kidney disease progression, and mitigating osteoarthritis pain, paving the way for highly individualized, treat-to-target metabolic care. In bone health, a review in The Journal of Clinical Endocrinology and Metabolism addresses the critical clinical gap of imminent fracture risk [7]. This refers to the highly elevated, transient risk of sustaining a subsequent fragility fracture within 12 to 24 months of an initial sentinel fracture, a risk that peaks dramatically within the first 3 to 6 months. The authors argue that traditional bone density and risk assessment tools are designed to project 10-year fracture risks, which often fails to capture the immediate clinical urgency of this post-fracture window. Recognizing this imminent risk is a call to action for secondary prevention, demanding the prompt initiation of rapid-acting bone-active therapies to interrupt the fracture cascade and protect vulnerable patients before a second, potentially devastating event occurs. For clinicians managing rare pituitary conditions, a systematic review in Clinical Endocrinology provides much-needed guidance on treating persistent or recurrent primary autoimmune hypophysitis after glucocorticoid therapy [9]. This rare disease often recurs, yet the role of non-glucocorticoid immunosuppressive therapies has been poorly defined. Analyzing 29 patients treated with agents such as azathioprine, mycophenolate mofetil, rituximab, methotrexate, infliximab, and tacrolimus, the review found that these therapies achieved a clinical remission rate of approximately 91%, a radiological remission rate of 72%, and a hormonal remission of 26%. Notably, rituximab achieved the highest radiological response rate at 100%, followed by mycophenolate mofetil at 66% and azathioprine at 37%. Adverse events occurred in about 20% of patients, suggesting that while non-glucocorticoid immunosuppressives are highly effective for recurrent disease, clinicians must carefully monitor for toxicities such as hepatitis and cytopenias. Finally, standardizing diagnostics remains a major hurdle in reproductive endocrinology. A report from the PCOS Challenge and Centers for Disease Control and Prevention stakeholder meeting, published in The Journal of Clinical Endocrinology and Metabolism, addresses the long-standing issue of highly variable testosterone reference ranges in women, adolescent girls, and children [4]. Despite assay standardization efforts, clinical decision-making for androgen excess disorders like polycystic ovary syndrome and congenital adrenal hyperplasia remains hindered by inconsistent laboratory reference intervals. The stakeholders outlined a 4-phase work plan to normalize and combine data across nine major clinical cohorts using validated Centers for Disease Control reference measurements, aiming to establish reliable, age- and sex-specific reference intervals for testosterone, anti-Müllerian hormone, and 11-oxygenated androgens.

If you only have time for one paper this week, make it the target trial emulation on GLP-1 receptor agonists and ischemic optic neuropathy risk by Reynolds and colleagues in the Annals of Internal Medicine [1]. This study, alongside the supporting Swedish cohort [2], provides crucial, reassuring data that helps us counsel patients on this highly publicized safety concern, demonstrating that the absolute risk of this serious ophthalmic condition is extraordinarily low and likely driven by baseline diabetes severity rather than the medication itself.

Here are the key takeaways from this week in Endocrinology: First, while GLP-1 receptor agonists show a slight relative risk increase for anterior ischemic optic neuropathy compared to SGLT-2 inhibitors, the absolute risk is extremely small, and much of this association appears to be due to residual confounding from diabetes severity. Second, adding a GLP-1 receptor agonist to basal insulin does not result in higher rates of complete insulin discontinuation compared to adding an SGLT-2 inhibitor or a DPP-4 inhibitor, with discontinuation rates hovering around 17% across all groups. Third, initiating a hybrid closed-loop system in patients with type 1 diabetes and impaired hypoglycemia awareness significantly reduces time below range, though their overall hypoglycemia burden remains higher than those with normal awareness. Fourth, administering prandial insulin 15 minutes before a meal in type 1 diabetes not only improves postprandial glycemia but also acutely increases myocardial microvascular blood flow. And fifth, for patients with recurrent primary autoimmune hypophysitis, non-glucocorticoid immunosuppressives offer high clinical and radiological remission rates, with rituximab showing the strongest radiological response.

That's your roundup for This Week in Endocrinology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.